Revvity Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Revvity ist ein dividendenzahlendes Unternehmen mit einer aktuellen Rendite von 0.26%. Das nächste Zahlungsdatum ist am 9th August, 2024 mit einem Ex-Dividendendatum von 19th July, 2024.

Wichtige Informationen

0.3%

Dividendenausschüttung

19%

Ausschüttungsquote

Durchschnittlicher Branchenertrag	0.4%
Nächster Dividendenzahlungstermin	09 Aug 24
Ex-Dividendendatum	19 Jul 24
Dividende pro Aktie	n/a
Gewinn pro Aktie	US$1.49
Erwartete Dividendenrendite in 3 Jahren	0.3%

Aktuelle Dividendenentwicklung

Recent updates

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 49% Undervalued

Jan 04

Revvity: More Than A Name Change Is Needed For PerkinElmer

Dec 29

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Dec 20

Is Revvity (NYSE:RVTY) Using Too Much Debt?

Oct 07

Revvity: Recent Investments, Acquisitions, Not Pulling Economic Weight (Rating Downgrade)

Oct 04

At US$108, Is Revvity, Inc. (NYSE:RVTY) Worth Looking At Closely?

Sep 22

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 40% Undervalued

Aug 17

Revvity: New Name - But New Investment Outlook? Reiterate Buy

Jul 18

Revvity (NYSE:RVTY) Seems To Use Debt Quite Sensibly

Jul 03

What Does Revvity, Inc.'s (NYSE:RVTY) Share Price Indicate?

Jun 17

Calculating The Fair Value Of Revvity, Inc. (NYSE:PKI)

May 16

We Think PerkinElmer (NYSE:PKI) Can Stay On Top Of Its Debt

Mar 28

When Should You Buy PerkinElmer, Inc. (NYSE:PKI)?

Mar 13

PerkinElmer Q4 2022 Earnings Preview

Feb 13

A Look At The Intrinsic Value Of PerkinElmer, Inc. (NYSE:PKI)

Feb 10

PerkinElmer: Capital Budgeting A Key Factor To The Investment Debate

Jan 31

Danaher earnings weigh on other life sciences tools, services companies

Jan 24

PerkinElmer says Q4 results will meet or exceed prior guidance

Jan 09

PerkinElmer (NYSE:PKI) Has A Pretty Healthy Balance Sheet

Dec 27

Is It Time To Consider Buying PerkinElmer, Inc. (NYSE:PKI)?

Dec 12

PerkinElmer receives FDA approval for EONIS assay for spinal muscular atrophy in newborns

Nov 14

PerkinElmer reports mixed Q3 earnings, initiates Q4 and updates FY22 pro forma guidance

Nov 08

PerkinElmer, Inc.'s (NYSE:PKI) Intrinsic Value Is Potentially 48% Above Its Share Price

Oct 28

Kommende Dividendenausschüttung

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: RVTY zahlt keine nennenswerte Dividende für den Markt US, daher muss nicht geprüft werden, ob die Zahlungen stabil sind.

Wachsende Dividende: RVTY zahlt keine nennenswerte Dividende für den Markt US, daher ist es nicht notwendig zu prüfen, ob die Zahlungen steigen.

Dividendenrendite im Vergleich zum Markt

Revvity Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von RVTY im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (RVTY)	0.3%
Untere 25 % des Marktes (US)	1.5%
Markt Top 25 % (US)	4.8%
Branchendurchschnitt (Life Sciences)	0.4%
Analystenprognose in 3 Jahren (RVTY)	0.3%

Bemerkenswerte Dividende: RVTYDie Dividende des Unternehmens (0.26%) ist im Vergleich zu den unteren 25 % der Dividendenzahler auf dem Markt US (1.53%) nicht bemerkenswert.

Hohe Dividende: RVTYDie Dividende des Unternehmens (0.26%) ist im Vergleich zu den besten 25% der Dividendenzahler auf dem Markt US (4.81%) niedrig.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: RVTY zahlt keine nennenswerte Dividende für den Markt US.

Barausschüttung an die Aktionäre

Cashflow-Deckung: RVTY zahlt keine nennenswerte Dividende für den Markt US.

Revvity Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Revvity, Inc. Declares Quarterly Dividend, Payable on August 9, 2024

Upcoming dividend of US$0.07 per share

Upcoming dividend of US$0.07 per share at 0.3% yield

Revvity Board Declares Quarterly Dividend, Payable on February 9, 2024

Upcoming dividend of US$0.07 per share at 0.3% yield

Revvity Declares Quarterly Dividend, Payable on November 10, 2023

Recent updates

Is Revvity (NYSE:RVTY) Using Too Much Debt?

First quarter 2024 earnings: EPS misses analyst expectations

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Dividend of US$0.07 announced

Revvity, Inc. Declares Quarterly Dividend, Payable on August 9, 2024

Revvity Unveils A New Era of Automated Tuberculosis Testing

Upcoming dividend of US$0.07 per share

Revvity, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Revvity: Enter Now As Reorganization Takes Shape

Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication

Revvity, Inc. Introduces New Workflow to Accelerate Newborn Sequencing Research

We Think Revvity (NYSE:RVTY) Can Stay On Top Of Its Debt

Investors Can Find Comfort In Revvity's (NYSE:RVTY) Earnings Quality

Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions

CEO, President & Director notifies of intention to sell stock

New minor risk - Earnings quality

Price target increased by 8.9% to US$122

Revvity Showcases Cutting-Edge Solutions at SLAS2024

Full year 2023 earnings: EPS exceeds analyst expectations

Revvity, Inc. Provides Revenue Guidance for the Full Year of 2024

Dividend of US$0.07 announced

Revvity, Inc., Annual General Meeting, Apr 23, 2024

Revvity, Inc. Announces Board Elections, Effective February 1, 2024

Should You Think About Buying Revvity, Inc. (NYSE:RVTY) Now?

Upcoming dividend of US$0.07 per share at 0.3% yield

Revvity, Inc. to Report Q4, 2023 Results on Feb 01, 2024

Revvity, Inc. Provides Revenue Guidance for the Fourth Quarter 2023

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 49% Undervalued

Revvity: More Than A Name Change Is Needed For PerkinElmer

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

Consensus EPS estimates fall by 15%

Price target decreased by 22% to US$107

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

New minor risk - Earnings quality

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Revvity Board Declares Quarterly Dividend, Payable on February 9, 2024

Upcoming dividend of US$0.07 per share at 0.3% yield

Revvity, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Is Revvity (NYSE:RVTY) Using Too Much Debt?

Revvity: Recent Investments, Acquisitions, Not Pulling Economic Weight (Rating Downgrade)

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

At US$108, Is Revvity, Inc. (NYSE:RVTY) Worth Looking At Closely?

Revvity, Inc. Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 40% Undervalued

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

New minor risk - Earnings quality

Second quarter 2023 earnings: EPS misses analyst expectations

Now 21% undervalued after recent price drop

Revvity Declares Quarterly Dividend, Payable on November 10, 2023

Revvity: New Name - But New Investment Outlook? Reiterate Buy

Revvity, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Upcoming dividend of US$0.07 per share at 0.2% yield

Revvity (NYSE:RVTY) Seems To Use Debt Quite Sensibly

Honeycomb Biotechnologies and Revvity Launch New Solutions to Expand the Frontiers of Single Cell Research

Now 22% undervalued after recent price drop

What Does Revvity, Inc.'s (NYSE:RVTY) Share Price Indicate?

Revvity, Inc. Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development

Calculating The Fair Value Of Revvity, Inc. (NYSE:PKI)

Consensus EPS estimates increase by 42%, revenue downgraded

Revvity, Inc. (NYSE:PKI) announces an Equity Buyback for $600 million worth of its shares.

First quarter 2023 earnings: EPS exceeds analyst expectations

Insider notifies of intention to sell stock

Upcoming dividend of US$0.07 per share at 0.2% yield

Insufficient new directors

We Think PerkinElmer (NYSE:PKI) Can Stay On Top Of Its Debt